Skip to main content

Table 1 Pharmacokinetic parameters for prednisolone after oral and intramuscular administration during growth-promoting and therapeutic treatment

From: Pharmacokinetic and urinary profiling reveals the prednisolone/cortisol ratio as a valid biomarker for prednisolone administration

 

Oral treatment

Intramuscular treatment

 

40 mg day−1

0.5 mg kg−1 day−1

40 mg day−1

0.5 mg kg−1 day−1

Cmax (μg L−1)

2.96 ± 1.50

7.01 ± 1.52

117 ± 25.8

156 ± 78.1

Tmax (h)

2.95 ± 0.820

3.85 ± 0.909

0.168 ± 0.063

0.866 ± 0.273

AUC0-tinf (h μg L−1)

26.1 ± 19.1

75.5 ± 25.0

232 ± 17.5

678 ± 11.5

ka (h−1)

0.363 ± 0.099

0.307 ± 0.129

17.1 ± 11.2

1.93 ± 0.395

T1/2a (h)

2.05 ± 0.588

2.53 ± 0.854

0.064 ± 0.052

0.370 ± 0.083

kel (h−1)

0.362 ± 0.091

0.245 ± 0.053

0.325 ± 0.046

0.132 ± 0.092

T1/2el (h)

2.04 ± 0.553

2.97 ± 0.728

2.16 ± 0.308

3.80 ± 0.499

Vd/F (L kg−1)

11.9 ± 4.89

30.1 ± 9.98

0.503 ± 0.215

2.47 ± 1.61

Cl/F (L h−1 kg−1)

4.66 ± 2.68

7.15 ± 1.97

0.346 ± 0.026

0.737 ± 0.012

  1. Average parameter values and SD were determined on the basis of 12 samples. Therapeutic treatment concerned the administration of 0.5 mg prednisolone kg−1 day−1, whereas during growth-promoting treatment 40 mg day−1 was administered